

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
9 November 2000 (09.11.2000)

PCT

(10) International Publication Number
WO 00/66581: A1(51) International Patent Classification⁷: **C07D 413/04**,
403/04, A61K 31/40, A61P 15/16

(21) International Application Number: PCT/US00/11844

(22) International Filing Date: 1 May 2000 (01.05.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/183,050 4 May 1999 (04.05.1999) US
09/552,544 19 April 2000 (19.04.2000) US(63) Related by continuation (CON) or continuation-in-part
(CIP) to earlier application:
US 09/552,544 (CON)
Filed on 19 April 2000 (19.04.2000)(71) Applicants (for all designated States except US): **AMERICAN HOME PRODUCTS CORPORATION** [US/US];
Five Giralda Farms, Madison, NJ 07840 (US). **LIGAND PHARMACEUTICALS, INC.** [US/US]; 10275 Science
Center Drive, San Diego, CA 92121 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **COLLINS, Mark**,
A. [GB/US]; 1011 New Hope Street, 13B, Norristown,
PA 19401 (US). **MACKNER, Valerie**, A. [US/US];
1300 Butler Pike, Apartment #262, Conshohocken, PA
19428 (US). **ZHI, Lin** [CN/US]; 7794 Roan Road, San
Diego, CA 92129 (US). **JONES, Todd**, K. [US/US];
546 Marview Drive, Solana Beach, CA 92075 (US).
TEGLEY, Christopher, M. [US/US]; 478 ThunderheadStreet, Thousand Oaks, CA 91360 (US). **WROBEL, Jay**,
E. [US/US]; 15 Rosetree Lane, Lawrenceville, NJ 08648
(US). **EDWARDS, James**, P. [US/US]; 8723 Hesby Court,
San Diego, CA 92129 (US).(74) Agents: **KODROFF, Cathy**, A. et al.; Howson and How-
son, Spring House Corporate Center, P.O. Box 457, Spring
House, PA 19477 (US).(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE,
DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(48) Date of publication of this corrected version:


30 May 2002

(15) Information about Correction:

see PCT Gazette No. 22/2002 of 30 May 2002, Section II

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: CYANOPYRROLES AS PROGESTERONE RECEPTOR AGONISTS



(1)

(57) Abstract: This invention provides a progesterone receptor antagonist
of formula (1) having the structure wherein T is O, S, or absent; R₁, and
R₂ are each, independently, hydrogen, alkyl, substituted alkyl; or R₁ and
R₂ are taken together to form a ring and together contain -CH₂(CH₂)_nCH₂-,
-CH₂CH₂CMe₂CH₂CH₂-, -O(CH₂)_pCH₂-, -O(CH₂)_qO-, -CH₂CH₂OCH₂CH₂-, or
-CH₂CH₂NR₇CH₂CH₂-, n=1-5; p=1-4; q=1-4; R₃ is hydrogen, OH, NH₂, alkyl,
substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,
or COR^A; R^A is hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy,
aminoalkyl, or substituted aminoalkyl; R₄ is hydrogen, halogen, CN, NH₂,
alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl; R₅ is hydrogen, alkyl, or substituted
alkyl; R₆ is hydrogen, alkyl, substituted alkyl, or COR^B; R^B is hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy,
aminoalkyl, or substituted aminoalkyl; R₇ is hydrogen or alkyl; or a pharmaceutically acceptable salt thereof.

WO 00/66581 A1

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07D 413/04, 403/04, A61K 31/40, A61P 15/16		A1	(11) International Publication Number: WO 00/66581
			(43) International Publication Date: 9 November 2000 (09.11.00)
(21) International Application Number: PCT/US00/11844 (22) International Filing Date: 1 May 2000 (01.05.00) (30) Priority Data: 09/304,550 4 May 1999 (04.05.99) US 09/552,544 19 April 2000 (19.04.00) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 09/552,544 (CON) Filed on 19 April 2000 (19.04.00) (71) Applicants (for all designated States except US): AMERICAN HOME PRODUCTS CORPORATION [US/US]; Five Giralda Farms, Madison, NJ 07840 (US). LIGAND PHARMACEUTICALS, INC. [US/US]; 10275 Science Center Drive, San Diego, CA 92121 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): COLLINS, Mark, A. [GB/US]; 1011 New Hope Street, 13B, Norristown, PA 19401 (US). MACKNER, Valerie, A. [US/US]; 1300 Butler Pike, Apartment #262, Conshohocken, PA 19428 (US). ZHI, Lin [CN/US]; 7794 Roan Road, San Diego, CA 92129			(US). JONES, Todd, K. [US/US]; 546 Marview Drive, Solana Beach, CA 92075 (US). TEGLEY, Christopher, M. [US/US]; 478 Thunderhead Street, Thousand Oaks, CA 91360 (US). WROBEL, Jay, E. [US/US]; 15 Rosetree Lane, Lawrenceville, NJ 08648 (US). EDWARDS, James, P. [US/US]; 8723 Hesby Court, San Diego, CA 92129 (US). (74) Agents: KODROFF, Cathy, A. et al.; Howson and Howson, Spring House Corporate Center, P.O. Box 457, Spring House, PA 19477 (US). (81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: CYANOPYRROLES AS PROGESTERONE RECEPTOR AGONISTS

(57) Abstract

This invention provides a progesterone receptor antagonist of formula (1) having the structure wherein T is O, S, or absent; R₁, and R₂ are each, independently, hydrogen, alkyl, substituted alkyl; or R₁ and R₂ are taken together to form a ring and together contain -CH₂(CH₂)_nCH₂-, -CH₂CH₂CMe₂CH₂CH₂-, -O(CH₂)_pCH₂-, -O(CH₂)_qO-, -CH₂CH₂OCH₂CH₂-, or -CH₂CH₂NR₇CH₂CH₂-, n=1-5; p=1-4; q=1-4; R₃ is hydrogen, OH, NH₂, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, or COR^A; R^A is hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl; R₄ is hydrogen, halogen, CN, NH₂, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl; R₅ is hydrogen, alkyl, or substituted alkyl; R₆ is hydrogen, alkyl, substituted alkyl, or COR^B; R^B is hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl; R₇ is hydrogen or alkyl; or a pharmaceutically acceptable salt thereof.



(1)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

CYANOPYRROLES AS PROGESTERONE RECEPTOR AGONISTS

Background of the Invention

5 Intracellular receptors (IR) form a class of structurally related gene regulators known as "ligand dependent transcription factors" (R. M. Evans, *Science*, **240**, 889, 1988). The steroid receptor family is a subset of the IR family, including progesterone receptor (PR), estrogen receptor (ER), androgen receptor (AR), glucocorticoid receptor (GR), and mineralocorticoid receptor (MR).


10 The natural hormone, or ligand, for the PR is the steroid progesterone, but synthetic compounds, such as medroxyprogesterone acetate or levonorgestrel, have been made which also serve as ligands. Once a ligand is present in the fluid surrounding a cell, it passes through the membrane *via* passive diffusion, and binds to the IR to create a receptor/ligand complex. This complex binds to specific gene
15 promoters present in the cell's DNA. Once bound to the DNA the complex modulates the production of mRNA and protein encoded by that gene.

 A compound that binds to an IR and mimics the action of the natural hormone is termed an agonist, whilst a compound that inhibits the effect of the hormone is an antagonist.


20 PR agonists (natural and synthetic) are known to play an important role in the health of women. PR agonists are used in birth control formulations, typically in the presence of an ER agonist, alternatively they may be used in conjunction with a PR antagonist. ER agonists are used to treat the symptoms of menopause, but have been associated with a proliferative effect on the uterus that can lead to an increased risk of
25 uterine cancers. Co-administration of a PR agonist reduces or ablates that risk.

 The compounds of this invention have been shown to act as competitive inhibitors of progesterone binding to the PR and act as agonists in functional models, either/or *in-vitro* and *in-vivo*. These compounds may be used for contraception, in the treatment of fibroids, endometriosis, breast, uterine, ovarian and prostate cancer, and
30 post menopausal hormone replacement therapy.


Jones *et al* (US 5,688,810) is the PR antagonist dihydroquinoline A.

**A**

5 Jones *et al* described the enol ether B (US 5,693,646) as a PR ligand.




**B**

10 Jones *et al* described compound C (US 5,696,127) as a PR ligand.


**C**

Zhi *et al* described lactones D, E and F as PR antagonists (*J. Med. Chem.* **41**,
15 291, 1998).


3

**D****E****F**

Zhi *et al* described the ether **G** as a PR antagonist (*J. Med. Chem.* **41**, 291,
5 1998).


**G**

Combs *et al* disclosed the amide **H** as a ligand for the PR (*J. Med. Chem.* **38**,
10 4880, 1995).


**H**

15 Perlman *et al* described the vitamin D analog **I** as a PR ligand (*Tetrahedron. Lett.* **35**, 2295, 1994).


4



Hamann *et al* described the PR antagonist **J** (*Ann. N.Y. Acad. Sci.* 761, 383,
5 1995).




Chen *et al* described the PR antagonist **K** (Chen *et al*, POI-37, 16th Int. Cong.
10 Het. Chem., Montana, 1997).



Kurihari *et al* described the PR ligand **L** (*J. Antibiotics* 50, 360, 1997).

15




5

L

Kuhla *et al* claimed the oxindole M as a cardiotonic (WO 86/03749).


5



M

Weber claimed the oxindole N for cardiovascular indications (WO 91/06545).


10



N

Fischer *et al* claim a preparation for making compounds which include the generic structure O (US 5453516).


15



O

R = various


20 Singh *et al* described the PDE III inhibitor P (*J. Med. Chem.* 37, 248, 1994).




6

P


Andreani *et al* described the cytotoxic agent **Q** (*Acta. Pharn. Nord.* **2**, 407, 1990).

**Q**

Binder *et al* described structure **R** which is an intermediate for preparing COX II inhibitors (WO 97/13767).

**R**

Walsh (A.H. Robins) described the oxindole **S** as an intermediate (US 4440785, US 4670566).

**S**


R1 = F, Cl, Br, alkyl, NH₂

R2 = alkyl, alkoxy, F, Cl, NH₂, CF₃

20


Bohm *et al* claim the oxindole **T** as cardiovascular agents (WO 91/06545).

7

**T**


Bohm *et al* include the generic structure U (WO 91/04974).

5

**U**


A Japanese patent contains the generic structure V (JP 63112584 A).

10


**V**

Boar *et al* described the dioxolane W as an intermediate for preparation of acetylcholinesterase inhibitors (WO 93/12085 A1).

15





**W**

Kende *et al* described methodology for preparing 3,3-substituted oxindoles, e.g., **X**, that was utilized in the present invention (*Synth. Commun.* **12**, 1, 1982).

**X**


There are numerous literature reports that disclose a number of benzoxazin-2-ones. However, none of these examples in these patents contain substituents necessary for the compounds to be active as progesterone receptor modulators.

Among these publications, Narr *et al* (German Patent, DE 3633861, CA 109:22973) claimed that imidazobenzoxazinones, e.g. **Y**, as cardotonics; Benzoxazin-2-ones, such as brofoxine (**Z**), being active as an anxiolytic was reported by Hartmann *et al* (*Proc. West. Pharmacol. Soc.* **21**, 51-55 (1978)); More recently, a number of patents (e.g., Young *et al* WO95/20389; Christ *et al.* WO98/14436) claimed quinazolin-2-ones and benzoxazin-2-ones such as compounds **AA** and **BB** as inhibitors of HIV reverse transcriptase.

**Y****Z****AA****BB**

DESCRIPTION OF THE INVENTION

This invention provides progesterone receptor agonists of Formula 1 having the structure



1

wherein

10 T is O, S, or absent;

R₁, and R₂ are each, independently, hydrogen, alkyl, substituted alkyl; or

R₁ and R₂ are taken together form a ring and together contain -CH₂(CH₂)_nCH₂-,
-CH₂CH₂CMe₂CH₂CH₂-, -O(CH₂)_pCH₂-, -O(CH₂)_qO-, -CH₂CH₂OCH₂CH₂-,
or -CH₂CH₂NR₇CH₂CH₂-;

15 n = 1-5;

p = 1-4;

q = 1-4

R₃ is hydrogen, OH, NH₂, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl,
substituted alkynyl, or COR^A;

20 R^A is hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or
substituted aminoalkyl;

R₄ is hydrogen, halogen, CN, NH₂, alkyl, substituted alkyl, alkoxy, substituted alkoxy,
aminoalkyl, or substituted aminoalkyl;

R₅ is hydrogen, alkyl, or substituted alkyl;


25 R₆ is hydrogen, alkyl, substituted alkyl, or COR^B;

R^B is hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or
substituted aminoalkyl;

R₇ is hydrogen or alkyl;

or a pharmaceutically acceptable salt thereof, which are useful for contraception, in the treatment of fibroids, endometriosis, breast, uterine, ovarian and prostate cancer, and post menopausal hormone replacement therapy

5 Preferred compounds of this invention are those having the structure:



1

10 wherein

T is O, or absent;

R₁, and R₂ are each, independently, hydrogen, alkyl, substituted alkyl; or

R₁ and R₂ are taken together form a ring and together contain -CH₂(CH₂)_nCH₂- ;

n = 1-5;

15 R₃ is hydrogen;

R₄ is hydrogen or halogen;

R₅ is hydrogen or alkyl;

R₆ is hydrogen or alkyl;

or a pharmaceutically acceptable salt thereof.

20 The compounds of this invention may contain an asymmetric carbon atom and some of the compounds of this invention may contain one or more asymmetric centers and may thus give rise to optical isomers and diastereoisomers. While shown without respect to stereochemistry in Formula 1, the present invention includes such optical isomers and diastereoisomers; as well as the racemic and resolved, enantiomerically
25 pure R and S stereoisomers; as well as other mixtures of the R and S stereoisomers and pharmaceutically acceptable salts thereof.

The term "alkyl" is used herein to refer to both straight- and branched-chain saturated aliphatic hydrocarbon groups having 1-6 carbon atoms; "alkenyl" includes both straight- and branched-chain alkyl group of 2-6 carbon atoms containing at least one carbon-carbon double bond; "alkynyl" group includes both straight- and branched-chain alkyl group of 2-6 carbon atoms with at least one carbon-carbon triple bond.

The terms "substituted alkyl", "substituted alkenyl", and "substituted alkynyl" refer to alkyl, alkenyl, and alkynyl as containing one or more substituents from the group including halogen, CN, OH, NO₂, amino, aryl, heterocyclic, substituted aryl, substituted heterocyclic, alkoxy, aryloxy, substituted alkyloxy, alkylcarbonyl, alkylcarboxy, alkylamino, arylthio. These substituents may be attached to any carbon of alkyl, alkenyl, or alkynyl group provided that the attachment constitutes a stable chemical moiety.

The term "thioalkyl" is used herein to refer to the SR group, where R is alkyl or substituted alkyl.

The term "alkoxy" is used herein to refer to the OR group, where R is alkyl or substituted alkyl.

The term "aryloxy" is used herein to refer to the OR group, where R is aryl or substituted aryl.

The term "alkylcarbonyl" is used herein to refer to the RCO group, where R is alkyl or substituted alkyl.

The term "alkylcarboxy" is used herein to refer to the COOR group, where R is alkyl or substituted alkyl. This term is also referred to as alkoxycarbonyl.


The term "aminoalkyl" refers to both secondary and tertiary amines wherein the alkyl or substituted alkyl groups may be either same or different and the point of attachment is on the nitrogen atom.

The term "halogen" is defined as Cl, Br, F, and I.

Pharmaceutically acceptable salts can be formed from organic and inorganic acids, for example, acetic, propionic, lactic, citric, tartaric, succinic, fumaric, maleic, malonic, mandelic, malic, phthalic, hydrochloric, hydrobromic, phosphoric, nitric,

sulfuric, methanesulfonic, naphthalenesulfonic, benzenesulfonic, toluenesulfonic, camphorsulfonic, and similarly known acceptable acids. Salts may also be formed from inorganic bases, preferably alkali metal salts, for example, sodium, lithium, or potassium, and organic bases, such as ammonium, mono-, di-, and trimethylammonium, mono-, di- and triethylammonium, mono-, di- and tripropylammonium (iso and normal), ethyldimethylammonium, benzyldimethylammonium, cyclohexylammonium, benzylammonium, dibenzylammonium, piperidinium, morpholinium, pyrrolidinium, piperazinium, 1-methylpiperidinium, 4-ethylmorpholinium, 1-isopropylpyrrolidinium, 1,4-dimethylpiperazinium, 1-n-butyl piperidinium, 2-methylpiperidinium, 1-ethyl-2-methylpiperidinium, mono-, di- and triethanolammonium, ethyl diethanolammonium, n-butylmonoethanolammonium, tris(hydroxymethyl)methylammonium, phenylmonoethanolammonium, and the like.

The compounds of this invention were be prepared according to the following schemes from commercially available starting materials or starting materials which can be prepared using literature procedures. These schemes show the preparation of representative compounds of this invention.




Scheme 1

20

According to scheme 1, commercially available oxindole 4 is treated with a strong organo-metallic base (e.g., butyl lithium, lithium diisopropylamide, potassium hexamethyldisilazide) in an inert solvent (e.g. THF, diethyl ether) under nitrogen at reduced temperature (ca. -20°C) (Kende, et al, *Synth. Commun.* 12, 1, 1982). The resulting di-anion then is treated with excess electrophile such as an alkyl halide,

25

preferably an iodide. If R_1 and R_2 are to be joined such as the product 5 contains a spirocycle at position 3, then the electrophile should be bifunctional, i.e. a diiodide. Subsequent bromination of 5 proceeds smoothly with bromine in acetic acid (an organic co-solvent such as dichloromethane may be added as required) in the presence of sodium acetate, to afford the aryl bromide 6. The bromide 6 is reacted with a palladium salt (e.g., tetrakis(triphenylphosphine)palladium(0) or palladium acetate), in a suitable solvent (e.g., THF, dimethoxyethane, acetone, ethanol or toluene) at room temperature under an inert atmosphere (argon, nitrogen). The mixture is then treated with pyrrole 2-boronic acid (*Synthesis* 613, 1991) and a base (potassium carbonate, triethylamine, potassium phosphate) in water or fluoride source (cesium fluoride) under anhydrous conditions. Treatment of the biaryl compound 7 with chlorosulfonyl isocyanate followed by an excess of DMF at low temperature produces the protected cyanopyrrole 8. Removal of the *tert*-butyloxycarbonyl (BOC) protecting group *via* standard conditions (e.g., TFA/dichloromethane, aqueous NaOH, thermolysis) produces the required final product which is purified by standard means.



Scheme 2

As depicted in Scheme 2, an appropriately substituted ortho-amino benzoic acid, or derivative (such as ethyl ester) 10 is treated with a suitable organometallic reagent, e.g., Grignard reagent, in appropriate nonprotic solvents (e.g., THF, ether, toluene) under an inert atmosphere such as argon or nitrogen at -78°C to room temperature to give ortho-amino carbinol 11. Ring closure of carbinol 11 to yield

benzoxazin-2-ones **12** is commonly effected by a condensing agent (e.g., carbonyldiimidazole, phosgene, dimethylcarbonate, diethylcarbonate) in a suitable nonprotic solvent (e.g., THF, ether, toluene) at temperatures in the range of room temperature to 65 °C. The pyrrole ring is attached to this platform by employing a
5 suitable coupling reaction (e.g., Suzuki, Stille) to give the biaryl **13**. These reactions are performed in the presence of suitable catalyst (e.g., palladium or nickel complexes often with phosphino ligands, e.g., Ph₃P, dppf, dppe or palladium salts such as palladium acetate) and a base: the commonly used bases include (but are not limited to) sodium bicarbonate, sodium carbonate, potassium phosphate, barium carbonate,
10 potassium acetate, or cesium fluoride. The most commonly used solvents in these reactions include benzene, DMF, isopropanol, ethanol, DME, ether, acetone or a mixture of any one of these solvent and water. The coupling reaction generally is executed under an inert atmosphere such as nitrogen or argon at temperatures ranging from room temperature to 95 °C. Treatment of the biaryl compound **13** with
15 chlorosulfonyl isocyanate followed by an excess of DMF at low temperature produces the protected cyanopyrrole **14**. Removal of the *tert*-butyloxycarbonyl (BOC) protecting group *via* standard conditions (e.g., TFA/dichloromethane, aqueous NaOH, thermolysis) produces the required final product **15** which is purified by standard means.

20 The compounds of this invention are progestational agonists, and are therefore useful as oral contraceptives (male and female), in hormone replacement therapy (particularly when combined with an estrogen), in the treatment of endometriosis, luteal phase defects, benign breast and prostatic diseases and prostatic, breast, ovarian, uterine and endometrial cancers.

25 The compounds of this invention can be used alone as a sole therapeutic agent or can be used in combination with other agents, such as other estrogens, progestins, or androgens.

The compounds of this invention can be formulated neat or with a pharmaceutical carrier for administration, the proportion of which is determined by the
30 solubility and chemical nature of the compound, chosen route of administration and standard pharmacological practice. The pharmaceutical carrier may be solid or liquid.

A solid carrier can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents; it can also be an encapsulating material. In powders, the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99% of the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidone, low melting waxes and ion exchange resins.

Liquid carriers are used in preparing solutions, suspensions, emulsions, syrups, elixirs and pressurized compositions. The active ingredient can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats. The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (partially containing additives as above, e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g. glycols) and their derivatives, lethicins, and oils (e.g. fractionated coconut oil and arachis oil). For parenteral administration, the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are useful in sterile liquid form compositions for parenteral administration. The liquid carrier for pressurized compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellant.

Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. The compounds of this invention can also be administered orally either in liquid or solid composition form.

The compounds of this invention may be administered rectally or vaginally in the form of a conventional suppository. For administration by intranasal or intrabronchial inhalation or insufflation, the compounds of this invention may be formulated into an aqueous or partially aqueous solution, which can then be utilized in

the form of an aerosol. The compounds of this invention may also be administered transdermally through the use of a transdermal patch containing the active compound and a carrier that is inert to the active compound, is non toxic to the skin, and allows delivery of the agent for systemic absorption into the blood stream via the skin. The carrier may take any number of forms such as creams and ointments, pastes, gels, and occlusive devices. The creams and ointments may be viscous liquid or semisolid emulsions of either the oil-in-water or water-in-oil type. Pastes comprised of absorptive powders dispersed in petroleum or hydrophilic petroleum containing the active ingredient may also be suitable. A variety of occlusive devices may be used to release the active ingredient into the blood stream such as a semipermeable membrane covering a reservoir containing the active ingredient with or without a carrier, or a matrix containing the active ingredient. Other occlusive devices are known in the literature.

The dosage requirements vary with the particular compositions employed, the route of administration, the severity of the symptoms presented and the particular subject being treated. Based on the results obtained in the standard pharmacological test procedures, projected daily dosages of active compound would be 0.02 $\mu\text{g/kg}$ - 750 $\mu\text{g/kg}$. Treatment will generally be initiated with small dosages less than the optimum dose of the compound. Thereafter the dosage is increased until the optimum effect under the circumstances is reached; precise dosages for oral, parenteral, nasal, or intrabronchial administration will be determined by the administering physician based on experience with the individual subject treated. Preferably, the pharmaceutical composition is in unit dosage form, e.g. as tablets or capsules. In such form, the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient; the unit dosage forms can be packaged compositions, for example, packaged powders, vials, ampoules, pre filled syringes or sachets containing liquids. The unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form.

The following provides the preparation of representative compounds of this invention.

Example 1

5-(4,4-Dimethyl-2-oxo-1,4-dihydro-2H-benzo [d] [1,3] oxazin-6-yl)-1H-pyrrole-2-carbonitrile

5 A solution of 2-amino-5-bromobenzoic acid (10g, 46 mmol) in dry THF (200 mL) was treated at -78 °C under nitrogen with a solution of methylmagnesium bromide in ether (3.0 M, 90 mL, 270 mmol). The reaction mixture was slowly warmed to ambient temperature, kept stirring for 48 hours under nitrogen and then poured into a cold 0.5 N aqueous hydrochloride solution (300 mL). The mixture was
10 neutralized with aqueous 1 N sodium hydroxide solution and ethyl acetate (300 mL) was added. The organic layer was separated and aqueous layer was extracted with ethyl acetate (3x100 mL). The combined organic layers were washed with brine and dried (MgSO₄). After removal of solvent *in vacuo*, the residue was purified by a silica gel flash chromatography (hexane:ethyl acetate/3:2) to give 2-(2-amino-5-
15 bromophenyl)propan-2-ol as an off-white solid (6g, 57%): mp 62-63 °C; ¹H-NMR (CDCl₃) δ 7.19 (d, 1H, *J* = 2.3 Hz), 7.12 (dd, 1H, *J* = 8.4, 2.3 Hz), 6.51 (d, 1H, *J* = 8.4 Hz), 4.70 (s, 2H), 1.82 (s, 1H), 1.65 (s, 6H).

 To a solution of 2-(2-amino-5-bromophenyl)propan-2-ol (18g, 78 mmol) in dry THF (150 mL) was added 1,1'-carbonyldiimidazole (15.5g, 94 mmol) under nitrogen.
20 The reaction solution was heated at 50 °C overnight. The solvent was removed *in vacuo* and the residue was dissolved in ethyl acetate (100 mL). The solution was washed with 1N aqueous hydrochloride solution (2x40 mL), brine (20 mL), and dried with MgSO₄. After removal of the solvent *in vacuo*, 6-bromo-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one was obtained as a white solid (20 g, 100%): mp
25 199-200 °C; ¹H-NMR (DMSO-d₆) δ 10.32 (s, 1H, D₂O exchangeable), 7.48 (d, 1H, *J* = 2.1 Hz), 7.43 (dd, 1H, *J* = 8.5, 2.1 Hz), 6.84 (d, 1H, *J* = 8.4 Hz), 1.61 (s, 6H).

 A solution of 6-bromo-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one (5.0 g, 20 mmol) and tetrakis(triphenylphosphine)palladium(0) (580 mg, 0.5 mmol) in toluene (200 mL) was stirred under a flow of nitrogen for 25 min. To the solution was
30 added sequentially 1-*tert*-butoxycarbonylpyrrole-2-boronic acid (8.24 g, 39 mmol) in absolute ethanol (50 mL) and potassium carbonate (5.39 g, 39 mmol) in water (50

mL). The mixture was heated to 80 °C for 16 h and allowed to cool. The reaction mixture was poured into aqueous saturated sodium bicarbonate solution (200 mL) and extracted with ethyl acetate (3 x 200 mL). The organic layers were combined, washed with water (200 mL) and brine (100 mL) and dried over magnesium sulfate. The solution was filtered, concentrated *in vacuo*, and the residue was purified by flash column chromatography on silica gel (30% ethyl acetate/hexane) to give 2-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-benzo [d] [1,3] oxazin-6-yl)-pyrrole-1-carboxylic acid *tert*-butyl ester (4.0 g, 58%) as a tan solid, mp 172-173 °C.

To a solution of 2-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-benzo [d] [1,3] oxazin-6-yl)-pyrrole-1-carboxylic acid *tert*-butyl ester (2.0 g, 5.8 mmol) in THF (anhydrous, 50 mL) at -78 °C was added chlorosulfonyl isocyanate (0.66 mL, 6.7 mmol). After 90 min, DMF (9 mL, 116 mmol) was added and the reaction was allowed to warm to room temperature. The reaction mixture was poured into water (50 mL) and extracted with ethyl acetate (2 x 50 mL). The organic layers were combined, washed with brine (50 mL), dried over magnesium sulfate, filtered and concentrated *in vacuo*. Purification via flash column chromatography on silica gel (30% ethyl acetate/hexane) gave 2-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-benzo [d] [1,3] oxazin-6-yl)-5-cyano-pyrrole-1-carboxylic acid *tert*-butyl ester (1.1 g, 52%) as a white powder, mp 165-167 °C. ¹H NMR (*d*₆-DMSO, 300 MHz) δ 1.36 (s, 9H), 1.61 (s, 6 H), 6.44 (d, 1 H, *J* = 3.7 Hz), 6.92 (d, 1 H, *J* = 8.2 Hz), 7.27-7.32 (m, 2 H), 7.36 ('d', 1 H, *J* = 1.5 Hz), 10.36 (s, 1 H). MS (EI) *m/z* 367 [M]⁺.

2-(4,4-Dimethyl-2-oxo-1,4-dihydro-2H-benzo [d] [1,3] oxazin-6-yl)-5-cyano-pyrrole-1-carboxylic acid *tert*-butyl ester (1 g, 2.7 mmol) was placed in a 25 mL round bottomed flask stoppered with a rubber septum and equipped with a nitrogen inlet and a needle to allow gaseous outflow. A vigorous flow of nitrogen was maintained as the flask was placed in an oil bath and heated to 160 °C. After 20 min at this temperature, the flask was removed from the oil bath and allowed to cool. The yellow residue was washed into a larger flask with dichloromethane/ethyl acetate and adsorbed onto a small amount of silica gel. Purification by flash column chromatography on silica gel (40% ethyl acetate/hexane) gave the title compound (340 mg, 47%) as a yellow

powder, mp 241-242 °C. ¹H NMR (*d*₆-DMSO, 300 MHz) δ 1.65 (s, 6 H), 6.67 (d, 1 H, *J* = 3.9 Hz), 6.91 (d, 1 H, *J* = 8.3 Hz), 6.98 (d, 1 H, *J* = 3.9 Hz), 7.61 (dd, 1 H, *J* = 1.8, 8.3 Hz), 7.65 ('d', 1 H, *J* = 1.6 Hz), 10.32 (s, 1 H), 12.54 (bs, 1 H). MS (EI) *m/z* 267 M⁺. Anal. Calcd. For C₁₅H₁₃N₃O₂: C, 67.41; H, 4.90; N, 15.72. Found: C, 67.19; H, 4.96; N, 15.35.

Example 2

5-(2'-Oxo-2',3'-dihydrospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-2-cyanopyrrole

A solution of oxindole (25 g, 0.19 mol) in anhydrous tetrahydrofuran (800 mL) was cooled to -20°C, then *n*-butyllithium (2.5M in hexanes, 152 mL, 0.38 mol) was added slowly followed by *N,N,N',N'*-tetramethylethylenediamine (51 mL, 0.38 mol). After 15 min. 1,5-diiodopentane (174 g, 0.54 mol) was added slowly and the mixture was allowed to warm to room temperature. After stirring for 16 h saturated aqueous ammonium chloride solution (1L) and EtOAc (1L) were added. After 15 min. the layers were separated and the aqueous phase was extracted EtOAc (x2). The combined organic layers were extracted with hydrochloric acid (1N), then washed with brine (500 mL), dried (MgSO₄), and concentrated to obtain an oil. The oil was triturated with hexane (200 mL) and benzene (20 mL). The precipitate was collected and dried *in vacuo* to obtain spiro[cyclohexane-1,3'-[3H]indol]-2'-(1'H)-one (26.3 g, 69.6%) as colorless crystals: mp 110-114°C; ¹H NMR (DMSO-*d*₆) δ 1.67 (m, 10H), 6.84 (d, 1H, *J* = 8 Hz), 6.94 (t, 1H, *J* = 8 Hz), 7.17 (t, 1H, *J* = 8 Hz), 7.44 (d, 1H, *J* = 8 Hz), 10.3 (s, 1H).

To a solution of spiro[cyclohexane-1,3'-[3H]indol]-2'-(1'H)-one (17.6 g, 9 mmol) in acetic acid (300 mL) was added sodium acetate (8.0 g, 0.1 mol) and bromine (14.6 g, 91 mmol) with stirring. After 30 min. at room temperature, the reaction mixture was partitioned between water and EtOAc. The aqueous phase was extracted twice with EtOAc. The combined organic layers were washed with water, dried (MgSO₄) and evaporated and the residue was triturated with hexane. The precipitate was collected, and dried *in vacuo* to obtain 5'-bromospiro[cyclohexane-1,3'-[3H]indol]-2'-(1'H)-one (16.5 g, 67%) as off-white crystals: mp 196 -199 °C; ¹H NMR

(DMSO- d_6) δ 1.62 (m, 10H), 6.8 (d, 1H, J = 6.8 Hz), 7.36 (d, 1H, J = 8.2, 1.8 Hz), 7.58 (dd, 1H, J = 8.2, 1.8 Hz), 10.44 (s, 1H).

To a solution of 5'-bromo-spiro[cyclohexane-1,3'-indolin]-2'-one (3.4 g, 12 mmol) in 1,2-DME (100 mL) under a nitrogen atmosphere, was added
5 tetrakis(triphenylphosphine)palladium(0) (70 mg, 5 mol%). After 15 min, 2-borono-1H-pyrrole-1-carboxylic acid, 1-tert butyl ester (1.3 eq, 3.31 g, 15.6 mmol) and a solution of K_2CO_3 (2.3 eq, 3.83 g, 27.6 mmol) in water (5 mL) were added sequentially. The solution was heated to 80 °C for 3 h and allowed to cool. The
10 reaction mixture was poured into water (200 mL) and extracted with EtOAc (2 \times 100 mL). The organic layers were combined, washed with brine (150 mL) and dried over $MgSO_4$. The solution was filtered, concentrated *in vacuo*, and the residue was purified by flash column chromatography on silica gel (eluting with 30% EtOAc/hexane) to give 2-(1',2'-dihydro-2'-oxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-1H-pyrrole-1-carboxylic acid, tert-butyl ester (3.4 g, 76%) as a white powder, mp 177 °C. 1H NMR
15 ($CDCl_3$; 300 MHz) δ 1.38 (s, 9 H), 1.59-1.93 (m, 10 H), 6.18 (m, 1 H), 6.23 (t, 1H, 3 Hz), 6.91 (d, 1 H, J =8 Hz), 7.21 (d, 1 H, J =8 Hz), 7.34 (m, 1 H), 7.44 (s, 1 H), 8.33 (br s, 1 H, D_2O ex). MS ((+)-APCI) m/z 367 [(M+H) $^+$]. Anal. Calcd for $C_{22}H_{26}N_2O_3$: C, 72.11; H, 7.15; N, 7.64. Found: C, 71.7; H, 7.16; N, 7.5.

To a solution of 2-(1',2'-dihydro-2'-oxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-1H-pyrrole-1-carboxylic acid, tert-butyl ester (0.75 g, 2 mmol) in THF (anhydrous,
20 20 mL) at -78 °C was added chlorosulfonyl isocyanate (1.15 eq, 0.23 mL, 2.3 mmol). After 90 min, DMF (20 eq, 3.6 mL, 46 mmol) was added and the reaction was allowed to warm to room temperature. The reaction mixture was poured into water (50 mL) and extracted with ethyl acetate (2 \times 50 mL). The organic layers were combined,
25 washed with brine (50 mL), dried over magnesium sulfate, filtered and concentrated *in vacuo*. Purification via flash column chromatography on silica gel (30% ethyl acetate/hexane) gave 5-(2'-oxo-2',3'-dihydrospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-2-cyanopyrrole-1-carboxylic acid, tert-butyl ester (0.5 g, 63%) as an oil which crystallized from acetone to give white crystals, mp 156 °C. 1H NMR (d_6 -DMSO, 400
30 MHz) δ 1.32 (s, 9H), 1.50 (m, 3 H), 1.60-1.70 (m, 5 H), 1.75-1.85 (m, 2 H), 6.38 (d,

1 H, $J = 3.7$ Hz), 6.87 (d, 1 H, $J = 7.9$ Hz), 7.18 (dd, 1 H, $J = 1.5, 7.9$ Hz), 7.27 (d, 1 H, $J = 3.7$ Hz), 7.48 (d, 1 H, $J = 1.8$ Hz), 10.42 (bs, 1 H). MS (EI) m/z 391 (M^+). Anal. Calcd for $C_{23}H_{25}N_3O_3$: C, 70.57; H, 6.44; N, 10.73. Found: C, 69.82; H, 6.46; N, 10.43.

- 5 5-(2'-Oxo-2',3'-dihydrospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-2-cyanopyrrole-1-carboxylic acid, tert-butyl ester (0.25 g, 0.8 mmol) was placed in a 5 mL round bottomed flask stoppered with a rubber septum and equipped with nitrogen inlet and a needle to allow gaseous outflow. A vigorous flow of nitrogen was maintained as the flask was placed in an oil bath and heated to 180 °C. After 5 min at this temperature, the flask was removed from the oil bath and allowed to cool. The black residue was washed into a larger flask with acetone and adsorbed onto a small amount of silica gel. Purification by flash column chromatography on silica gel (eluting with 30% EtOAc/hexane) gave the title compound (95 mg, 51 %) as a yellow oil which crystallized from dichloromethane to give a grey powder, mp 239 °C (dec). 1H NMR (DMSO- d_6 ; 300 MHz) δ 1.40-1.90 (m, 10H), 6.60 (m, 1H), 6.88 (d, 1H, $J=8.1$ Hz), 6.95 (m, 1H), 7.56 (dd, 1H, $J=1.8, 8.1$ Hz), 7.78 (d, 1H, $J=1.3$ Hz), 10.42 (s, 1 H), 12.50 (s, 1 H). MS (EI) m/z 291 (M^+). Anal. Calcd for $C_{18}H_{17}N_3O_1$: C, 74.20; H, 5.88; N, 14.42. Found: C, 66.63; H, 5.52; N, 12.46.
- 10
- 15

20

Example 3

2-(3,3-Dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-2-cyanopyrrole

- To a solution 2-(3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-pyrrole-1-carboxylic acid tert-butyl ester (0.39 g, 1.2 mmol) in THF (anhydrous, 9 mL) at -78 °C was added chlorosulfonyl isocyanate (1.15 eq, 0.12 mL, 1.4 mmol). After 120 min, DMF (20 eq, 1.8 mL, 23 mmol) was added and the reaction was allowed to warm to room temperature. The reaction mixture was poured into water (25 mL) and extracted with ethyl acetate (2 x 50 mL). The organic layers were combined, washed with brine (50 mL), dried over magnesium sulfate, filtered and concentrated *in vacuo*. Purification via flash column chromatography on silica gel (1:3 ethyl acetate/hexane) gave 2-(3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-2-cyanopyrrole-1-carboxylic
- 25
- 30

acid tert-butyl ester (0.21 g, 50%) as a white solid: mp 158.6. ¹H NMR (DMSO-*d*₆; 300 MHz) δ 1.27 (s, 6H), 1.33 (s, 9H), 6.40 (d, 1H, *J*=3.8 Hz), 6.90 (d, 1H, *J*=8.0 Hz), 7.19 (dd, 1H, *J*=1.8, 8.0 Hz), 7.30 (d, 1H, *J*=1.5 Hz), 10.50 (s, 1 H). MS *m/z* 350 (M-H)⁺. Calcd for C₁₉H₂₂N₂O₃: C, 68.36; H, 6.02; N, 11.96. Found: C, 66.79; H, 6.03; N, 11.02.

2-(3,3-Dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-pyrrole-1-carboxylic acid *tert*-butyl ester (0.18 g, 0.51 mmol) was placed in a 50 mL round bottomed flask stoppered with a rubber septum and equipped with a nitrogen inlet and a needle to allow gaseous outflow. A vigorous flow of nitrogen was maintained as the flask was placed in an oil bath and heated to 160 °C. After 10 min at this temperature, the flask was removed from the oil bath and allowed to cool. The black residue was washed into a larger flask with acetone and adsorbed onto a small amount of fluorsil. Purification by flash column chromatography on silica gel (eluting with 1:3 acetone: hexane) gave the title compound (118 mg, 92%) as a white solid mp 255.9-257.9 °C. ¹H NMR (DMSO-*d*₆; 300 MHz) δ 1.29 (s, 6H), 6.60 (m, 1H), 6.89 (d, 1H, *J*=8.0 Hz), 6.96 (m, 1H), 7.55 (dd, 1H, *J*=1.4, 8.1 Hz), 7.69 (bs, 1H), 10.47 (s, 1 H), 12.48 (s, 1 H). MS *m/z* 250 (M-H)⁺. Calcd for C₂₀H₂₁N₃O₃: C, 71.7; H, 5.21; N, 16.72. Found: C, 71.16; H, 5.58; N, 16.09.

Example 4

5-(2'-Oxo-2',3'-dihydrospiro[cyclopentane-1,3'-[3H]indol]-5'-yl)-2-cyanopyrrole

A solution of 5'-bromospiro[cyclopentane-1,3'-[3H] indol]-2'(1'H)-one (2.0 g, 7.5 mmol) and tetrakis(triphenylphosphine)palladium(0) (430 mg, 0.3 mmol) in ethylene glycol dimethyl ether (50 mL) was stirred under a flow of nitrogen for 15 min. To the solution was added sequentially 1-*t*-butoxycarbonylpyrrole-2-boronic acid (2.1 g, 9.7 mmol) and potassium carbonate (2.4 g, 17 mmol) in water (10 mL). The mixture was heated to 80 °C for 3 h and allowed to cool. The reaction mixture was poured into water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The organic layers were combined, washed with brine (30 mL) and dried over magnesium sulfate. The solution was filtered and concentrated *in vacuo*. Crystallization from 20% ethyl

acetate/hexane gave 2-(1',2'-dihydro-2'-oxospiro[cyclopentane-1,3'-[3H]indol]-5'-yl)-1H-pyrrole-1-carboxylic acid, tert-butyl ester (2.2 g, 83%) as a white powder, mp 179-180.5 °C. ¹H NMR (DMSO-*d*₆, 400 MHz) δ 1.30 (s, 9H), 1.75-1.98 (m, 8 H), 6.16 (dd, 1 H, *J* = 1.8, 3.3 Hz), 6.22 ('t', 1 H, *J* = 3.3, 3.3 Hz), 6.79 (d, 1 H, *J* = 7.9 Hz), 7.08 (dd, 1 H, *J* = 1.8, 7.9 Hz), 7.14 ('d', 1 H, *J* = 1.5 Hz), 7.28 (dd, *J* = 1.9, 3.3 Hz), 10.30 (s, 1 H). MS (EI) *m/z* 352 [*M*⁺]. Anal. Calcd for C₂₁H₂₄N₂O₃: C, 71.57; H, 6.86; N, 7.95. Found: C, 71.08; H, 6.83; N, 7.74.

To a solution of 2-(1',2'-dihydro-2'-oxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-1H-pyrrole-1-carboxylic acid, tert-butyl ester (2.2 g, 6.0 mmol) in THF (anhydrous, 25 mL) was added at -78 °C chlorosulfonyl isocyanate (0.63 mL, 7.0 mmol). After 90 min, dimethylformamide (11 mL, 140 mmol) was added and the reaction was allowed to warm to room temperature. The reaction mixture was poured into water (50 mL) and extracted with ethyl acetate (2 x 50 mL). The organic layers were combined, washed with brine (50 mL), dried over magnesium sulfate, filtered and concentrated *in vacuo*. Purification via flash column chromatography on silica gel (30% ethyl acetate/hexane) gave 5-(2'-oxo-2',3'-dihydrospiro[cyclopentane-1,3'-[3H]indol]-5'-yl)-2-cyanopyrrole-1-carboxylic acid, tert-butyl ester (1.7 g, 75%) as white crystals, mp 167-169 °C. ¹H NMR (DMSO-*d*₆, 400 MHz) δ 1.34 (s, 9H), 1.75-1.98 (m, 8 H), 6.39 (d, 1 H, *J* = 3.7 Hz), 6.84 (d, 1 H, *J* = 7.9 Hz), 7.17 (dd, 1 H, *J* = 1.8, 7.9 Hz), 7.28 ('t', 2 H), 10.41 (s, 1 H). MS (ESI) *m/z* 376 [*M*-H]⁻. Anal. Calcd. for C₂₂H₂₃N₃O₃: C, 70.01; H, 6.14; N, 11.13. Found: C, 69.67; H, 6.38; N, 11.04.

5-(2'-Oxo-2',3'-dihydrospiro[cyclopentane-1,3'-[3H]indol]-5'-yl)-2-cyanopyrrole-1-carboxylic acid, tert-butyl ester (1 g, 2.7 mmol) was placed in a 25 mL round bottomed flask stoppered with a rubber septum and equipped with nitrogen inlet and a needle to allow gaseous outflow. A vigorous flow of nitrogen was maintained as the flask was placed in an oil bath and heated to 165 °C. After 20 min at this temperature, the flask was removed from the oil bath and allowed to cool. Crystallization from ethyl ether gave the title compound (600 mg, 79%) as a yellow powder, mp 285-286 °C. ¹H NMR (DMSO-*d*₆, 400 MHz) δ 1.75-2.03 (m, 8 H), 6.60 (dd, 1 H, *J* = 2.4, 3.7 Hz), 6.84 (d, 1 H, *J* = 8.1 Hz), 6.94 (dd, 1 H, *J* = 2.4, 3.7 Hz),

7.52 (dd, 1 H, $J = 1.8, 8.1$ Hz), 7.60 (d, 1 H, $J = 1.8$ Hz), 10.38 (s, 1 H), 12.45 (s, 1 H). MS (ESI) m/z 276 [M-H]⁻. Anal. Calcd. For C₁₇H₁₅N₃O: C, 73.63; H, 5.45; N, 15.15. Found: C, 73.24; H, 5.34; N, 14.96.

5

Example 5

5-(4,4-Dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile

To a solution of 5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrole-2-carbonitrile (1 eq, 71 mg, 0.27 mmol) in dimethylformamide (0.5 mL) was added potassium carbonate (5 eq, 0.18 g, 0.135 mmol). After 10 min., iodomethane (3 eq, .05 mL, 0.81 mmol) was added and the suspension was stirred for 2h, poured into water (5 mL) and extracted with ethyl acetate (3 x 5 mL). The layers were separated, the aqueous layer was extracted with ethyl acetate (3 x 10 mL) and the combined organic layer was washed with brine, dried over MgSO₄ and purified by flash column chromatography on silica gel eluting with 30% ethyl acetate/hexane to give 5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile (30 mg, 41%) as a white solid. ¹H NMR (300 MHz, *d*₆-DMSO) δ 1.64 (s, 6 H), 3.71 (s, 3 H), 6.33 (d, 1 H, $J = 4.1$ Hz), 6.98 (d, 1 H, $J = 8.0$ Hz), 7.03 (d, 1 H, $J = 4.1$ Hz), 7.39 (m, 2 H), 10.39 (s, 1 H). MS (APCI (-)) m/z 280 (M-H)⁻. Anal. calcd for C₁₆H₁₅N₃O₂, C, 68.3, H, 5.37, N, 14.9. Found, C, 68.4, H, 5.51, N, 14.6.

20

Example 6

General Method A

5-(4,4-Dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-ethyl-1H-pyrrole-2-carbonitrile

To a solution of 5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrole-2-carbonitrile (1.3 g, 5 mmol) in dimethylformamide (25 mL) was added potassium carbonate (1 g, 7.5 mmol), and iodoethane (0.4 mL, 5.1 mmol), and the mixture was stirred at room temperature for 3 hours. Ethylacetate and water were

30

added, the ethylacetate layer was separated, dried over magnesium sulfate, and concentrated *in vacuo*. The residue was recrystallized from ethylacetate/hexane to afford the title compound, m.p. 200-202 °C (0.4 g, 27%); ¹H-NMR (DMSO-d₆) δ 1.25 (t, *J* = 7.2 Hz, 3H), 1.64 (s, 6H), 4.07 (q, *J* = 7.2 Hz, 2H), 6.29 (d, *J* = 4.1 Hz, 1H),
5 7.0 (d, *J* = 8 Hz, 1H), 7.05 (d, *J* = 4.1 Hz, 1H), 7.34 (m, 2H), 10.42 (s, 1H). MS (ESI (-)) *m/z* 294 (M-H)⁺

Example 7

10 5-(4,4-dimethyl-2-oxo-1,4-Dihydro-2H-3,1-benzoxazin-6-yl)-1-prop-2-ynyl-1H-pyrrole-2-carbonitrile

5-(4,4-Dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrol-2-carbonitrile (0.74 g, 2.8 mmol) and propargylbromide (0.5 g, 4.2 mmol) were reacted, according to General Method A, to afford the title compound, m.p. 222-224 °C (0.13 g, 15%). ¹H-NMR (DMSO-d₆) δ 1.65 (s, 6H), 3.64 (t, *J* = 2.3 Hz, 1H), 4.85 (d, *J* =
15 2.3 Hz, 2H), 6.37 (d, *J* = 4 Hz, 1H), 7.01 (d, *J* = 8.2 Hz, 1H), 7.11 (d, *J* = 4 Hz, 1H), 7.43 (m, 2H), 10.45 (s, 1H), MS (APCI (-)) *m/z* 304 (M-H)⁺

Example 8

20 tert-butyl[2-cyano-5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrol-1-yl]acetate

5-(4,4-Dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrol-2-carbonitrile (5.4 g, 20 mmol) and *tert*-butylbromoacetate (4.64 g, 22 mmol) were reacted, according to General Method A, to afford the title compound, m.p. 188-190 °C (3 g, 40%). ¹H-NMR (DMSO-d₆) δ 1.35 (s, 9H), 1.62 (s, 6H), 4.8 (s, 2H), 6.35
25 (d, *J* = 4.3 Hz, 1H), 6.98 (d, *J* = 8.1 Hz, 1H), 7.09 (d, *J* = 4.3 Hz, 1H), 7.26 (m, 2H), 10.42 (s, 1H), MS (APCI (-)) *m/z* 380 (M-H)⁺

Example 9**[2-Cyano-5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrol-1-yl]acetic acid**

A solution of *tert*-butyl[2-cyano-5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrol-1-yl]acetate (2.2 g, 5.8 mmol), and sodium hydroxide (1.6 g, 40 mmol) in ethanol (200 ml) was heated to reflux for 2 hours. After cooling to room temperature the mixture was acidified with diluted hydrochloric acid, and extracted with ethylacetate. The ethylacetate solution was dried over magnesium sulfate, filtered, and concentrated in vacuo. Recrystallization from ethylacetate/hexane
10 afforded the title compound, m.p. 207 - 209 °C (1.2 g, 64 %); ¹H-NMR (DMSO-d₆) δ 1.61 (s, 6H), 4.77 (s, 2H), 6.35 (d, *J* = 4 Hz, 1H), 6.98 (d, *J* = 8.1 Hz, 1H), 7.09 (d, *J* = 4.1 Hz, 1H), 7.26 (m, 2H), 10.43 (s, 1H), MS (APCI (-)) *m/z* 324 (M-H)⁺.

Example 10**2-[2-cyano-5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrol-1-yl]-N-[2-(3-ethoxy-4-methoxyphenyl) ethyl]acetamide**

A solution of [2-cyano-5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrol-1-yl]acetic acid (0.6 g, 1.8 mmol), 3-ethoxy-4-methoxyphenylethylamine (0.36 g, 1.9 mmol), *di*iso-propylethylamine (0.26 g, 2 mmol), and O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (0.7 g, 1.8 mmol) in dimethylformamide (20 ml) was stirred at room temperature for 20 hours. The mixture was diluted with water and extracted with ethylacetate. The ethylacetate solution was washed with brine, dried over magnesium sulfate, and concentrated *in vacuo*. The residue was recrystallized from ethanol to
25 afford the title compound, m.p. 160-162 °C (0.2 g, 22 %): ¹H-NMR (DMSO-d₆) δ 1.3 (t, *J* = 6.9 Hz, 3H), 1.59 (s, 6H), 2.61 (t, 2H, *J* = 7 Hz), 3.29 (q, *J* = 6.9 Hz, 2H), 3.71 (s, 3H), 3.97 (q, *J* = 6.9 Hz, 2H), 4.6 (s, 2H), 6.32 (d, *J* = 5.1 Hz, 1H), 6.65 (dd, *J* = 7.6, 2.0 Hz, 1H), 6.77 (d, *J* = 2.3, 1H), 6.83 (d, *J* = 8.3 Hz, 1H), 6.96 (d, *J* = 8.7 Hz, 1H), 7.05 (d, *J* = 4.1 Hz, 1H), 7.26 (m, 2H), 8.3 (t, *J* = 6 Hz, 1H), 10.42 (s, 1H), MS
30 (APCI (+)) *m/z* 503 (M+H)⁺

Example 11**5-(4,4-Dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazine-6-yl)-1-pentyl-1H-pyrrole-2-carbonitrile**

5 5-(4,4-Dimethyl-oxo-1,4-dihydro-2H-3,1-benzoxazine-6-yl)-1H-pyrrole-carbonitrile (1.94 g, 7.3 mmol) was reacted, according to General Method A, with 1-iodopentane (1.5 g, 7.6 mmol) to afford the title compound, m.p. 128-131 °C (0.2 g, 8%); ¹H-NMR (DMSO-d₆) δ 0.73 (t, *J* = 7.3 Hz, 3H), 1.05 (m, 2H), 1.14 (m, 2H), 1.57 (m, 2H), 1.63 (s, 6H), 4.04 (t, *J* = 7.5 Hz, 2H), 6.28 (d, *J* = 4 Hz, 1H), 6.98 (d, *J* = 7.9 Hz, 1H), 7.04 (d, *J* = 4.5 Hz, 1H), 7.33 (dd, *J* = 8.9, 2.0 Hz, 1H), 7.37 (d, *J* = 2.2 Hz, 1H), 10.41 (s, 1H), MS (APCI (-)) *m/z* 336 (M-H)⁺

10

Example 12**5-(1,4,4-trimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrole-2-carbonitrile**

15 *tert*-Butyl 2-cyano-5-(1,4,4-trimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrole-1-carboxylate.

To a solution of 2-(4,4-Dimethyl-2-oxo-1,4-dihydro-2H-benzo [d] [1,3] oxazin-6-yl)-5-cyano-pyrrole-1-carboxylic acid *tert*-butyl ester (0.5 g, 1.4 mmol, 1 eq) in DMF (anhydrous, 25 mL) was added NaH (60% dispersion in oil, 65 mg, 1.6 mmol, 1.2 eq) at 0 °C. After 15 min, methyl iodide (0.25 mL, 4.1 mmol, 3 eq) was added and the reaction was allowed to warm to room temperature over night. The reaction mixture was poured into water (50 mL) and extracted with ethyl acetate (2 x 50 mL). The organic layers were combined, washed with brine (50 mL), dried over magnesium sulfate, filtered and concentrated *in vacuo* to give the product (0.5 g, 94%) as an off-white solid, mp 143-145 °C: ¹H NMR (300 MHz, *d*₆-DMSO) δ 1.38 (s, 9 H), 1.62 (s, 6 H), 3.33 (s, 3 H), 6.48 (d, 1 H, *J* = 3.8 Hz), 7.13 – 7.16 ('dd', 1 H), 7.33 (d, 1 H, *J* = 3.8 Hz), 7.40 – 7.43 (m, 2 H). MS (ESI (+)) [M+H]⁺ = 382. Anal. calcd. for C₂₁H₂₃N₃O₄: C, 66.13; H, 6.08; N, 11.02. Found: C, 65.46; H, 6.16; N, 11.02.

20

25

tert-Butyl 2-cyano-5-(1,4,4-trimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrole-1-carboxylate (180 mg, 0.47 mmol) was placed in a 25 mL round bottomed flask stoppered with a rubber septum and equipped with nitrogen inlet and a needle to allow gaseous outflow. A vigorous flow of nitrogen was maintained as the flask was placed in an oil bath and heated to 150 °C. After 20 min at this temperature, the flask was removed from the oil bath and allowed to cool. To the solid was added acetone/dichloromethane. The solid was filtered to give the product (100 mg, 76%) as an off-white solid, mp 256-7 °C (dec.): ¹H NMR (300 MHz, *d*₆-DMSO) δ 1.65 (s, 6 H), 3.33 (s, 3 H), 6.74 (dd, 1 H, *J* = 2.6, 3.6 Hz), 7.00 (dd, 1 H, *J* = 2.2, 3.8 Hz), 7.15 (d, 1 H, *J* = 8.5 Hz), 7.67 (d, 1 H, *J* = 1.9 Hz), 7.73 (dd, 1 H, *J* = 1.9, 8.5 Hz), 12.62 (s, 1 H). MS (ESI (+)) [M+H]⁺ = 282. Anal. calcd. for C₁₆H₁₅N₃O₂: C, 68.31; H, 5.37; N, 14.94. Found: C, 67.87; H, 5.42, N, 14.75.

Example 13

4-Bromo-5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile

To a solution of *tert*-butyl 6-(5-cyano-1-methyl-1H-pyrrol-2-yl)-4,4-dimethyl-2-oxo-2H-3,1-benzoxazine-1(4H)-carboxylate (1 eq, 1.94 g, 5.10 mmol) in THF (150 mL) at -78 °C was added N-bromosuccinimide (1.1 eq, 1.0 g, 5.61 mmol). The solution was allowed to warm and stir for 16 hours. Pyridine (1 mL) was added and the mixture was poured into water (150 mL), the layers were separated, the aqueous layer was extracted with ethyl acetate (3 x 10 mL) and the combined organic layer was washed with brine, dried over MgSO₄ and concentrated in vacuo. The product, *tert*-butyl 6-(3-bromo-5-cyano-1-methyl-1H-pyrrol-2-yl)-4,4-dimethyl-2-oxo-2H-3,1-benzoxazine-1(4H)-carboxylate was obtained by crystallization from 20% ethyl acetate/hexane as a white crystalline solid. ¹H NMR (300 MHz, *d*₆-DMSO) δ 1.56 (s, 9H), 1.71 (s, 6H), 3.65 (s, 3H), 7.30 (s, 1H), 7.44 (d, 1H, *J*=8.4Hz), 7.52 (d, 1H, *J*=8.4Hz), 7.55 (s, 1H). M/z (ESI (+)) 461 (M+H)⁺. Anal. calcd for C₂₁H₂₂N₃O₄, C, 54.8, H, 4.82, N, 9.13. Found, C, 54.9, H, 4.86, N, 9.1.

A solution of *tert*-butyl 6-(3-bromo-5-cyano-1-methyl-1H-pyrrol-2-yl)-4,4-dimethyl-2-oxo-2H-3,1-benzoxazine-1(4H)-carboxylate (1 eq, 0.4 g, 0.87 mmol) in THF was added to a solution of sodium ethoxide (3 eq, 0.18 g, 2.6 mmol) in ethanol (10 mL). The solution was heated at 80 °C for 1h then cooled to room temperature and concentrated *in vacuo*. The residue was dissolved in THF (10 mL) and 4N HCl (10 mL) was added. After heating to 60 °C for 16h the solution was cooled, poured into water and the layers were separated. The aqueous layer was extracted with ethyl acetate (3 x 10 mL) and the combined organic layer was washed with brine, dried over MgSO₄ and concentrated in *vacuo*. The product, (4-bromo-5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile (0.17 g, 54%) was obtained by crystallization from 20% ethyl acetate/hexane. ¹H NMR (300 MHz, *d*₆-DMSO) δ 1.64 (s, 6H), 3.62 (s, 3H), 7.02 (d, 1H, *J* = 8.2Hz), 7.34 (s, 1H), 7.35 (dd, 1H, *J* = 1.3, 8.2Hz), 7.40 (s, 1H), 10.47 (s, 1H). MS (ESI (-)) *m/z* 358/360 (M-H)⁺. Anal. calcd for C₁₆H₁₄N₃O₂Br, C, 53.4, H, 3.92, N, 11.7. Found, C, 52.6, H, 3.82, N, 11.2.

Example 14

5-(4,4-Dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1,4-dimethyl-1H-pyrrole-2-carbonitrile

A solution of 4-bromo-5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile (70 mg, 0.2 mmol), PhCNPdCl(PPh₃)₂ (cat., 7 mg) and tetramethyltin (10 eq, 0.35 g, 2 mmol) in HMPA (3 mL) was heated to 110 °C for 5 days. The solution was allowed to cool, poured into water (20 mL) and extracted with ethyl acetate (3 x 5 mL). The combined organic layer was washed with brine, dried over MgSO₄ and purified by flash column chromatography on silica gel eluting with 30% ethyl acetate/hexane to give 5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1,4-dimethyl-1H-pyrrole-2-carbonitrile (36 mg, 63%) as a white solid. ¹H NMR (300 MHz, *d*₆-DMSO) δ 1.64 (s, 6H), 1.97 (s, 3H), 3.56 (s, 3H), 6.87 (s, 1H), 7.00 (d, 2H, *J*=8.1Hz), 7.28 (dd, 1H, *J*=8.1, 1.6Hz), 7.32 (s, 1H), 10.40 (s,

1H). MS (ESI (-)) 294 (M-H)⁻. Anal. calcd for C₁₇H₁₇N₃O₂, C, 69.1, H, 5.8, N, 14.2. Found, C, 69.1, H, 5.72, N, 14.0.

Example 15

5 tert-Butyl 5-cyano-2-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-3-nitro-1H-pyrrole-1-carboxylate

To a solution of 2-(4,4-Dimethyl-2-oxo-1,4-dihydro-2H-benzo [d] [1,3] oxazin-6-yl)-5-cyano-pyrrole-1-carboxylic acid tert-butyl ester (3.0 g, 8.2 mmol, 1 eq) in acetic anhydride (50 mL) was added Cu(NO₃)₂·2.5 H₂O (1.04 g, 4.5 mmol, 0.55 eq).
10 After the reaction mixture stirred at room temperature for 24 h, it was poured into saturated aqueous sodium bicarbonate solution (100 mL) and extracted with ethyl acetate (2 x 100 mL). The organic layers were combined, washed with water (50 mL) and brine (50 mL), dried over magnesium sulfate, filtered and concentrated *in vacuo*. Purification by flash column chromatography (20% ethyl acetate/hexane) on silica gel
15 gave the product as a yellow solid (0.54 g, 16%). ¹H NMR (500 MHz, *d*₆-DMSO) δ 1.25 (s, 9 H), 1.60 (s, 6 H), 6.97 (d, 1 H, *J* = 8.2 Hz), 7.38 (dd, 1 H, *J* = 1.8, 8.2 Hz), 7.49 (d, 1 H, *J* = 1.8 Hz), 8.09 (s, 1 H), 10.47 (s, 1 H). MS (ESI (-)) [M-H]⁻ = 411. Anal. calcd. for C₂₀H₂₀N₄O₆: C, 58.25; H, 4.89; N, 13.59. Found: C, 58.72; H, 5.14, N, 13.39.

20

Example 16

4-Amino-5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrole-2-carbonitrile

A solution of 4-nitro-5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrole-2-carbonitrile (0.4 g, 1.28 mmol) in ethanol/water (5:1, 20 mL) was
25 treated sequentially with zinc powder (2.5 wt, 1.0 g) and ammonium chloride (5 wt, 2.0 g). The suspension was heated at 80 °C or 30 min, cooled to room temperature, poured into water (30 mL) and extracted with ethyl acetate (3 x 15 mL). The combined organic layer was washed with brine, dried over MgSO₄ and purified by
30 flash column chromatography on silica gel eluting with ethyl acetate to give 4-amino-

5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrole-2-
carbonitrile (0.29 g, 80%) as a yellow solid. ¹H NMR (500 MHz, *d*₆-DMSO) δ 1.63
(s, 6H), 4.29 (s, 2H), 6.39 (s, 1H), 6.89 (d, 1H, *J*=8.1Hz), 7.49 (s, 1H), 7.52 (dd, 1H,
J=8.1 and 2.3Hz), 10.25 (s, 1H), 11.76 (s, 1H). MS (ESI (-)) *m/z* 281 (M-H)⁺. Anal.
5 calcd for C₁₅H₁₄N₄O₂, C, 63.8, H, 5.00, N, 19.9. Found, C, 63.7, H, 5.10, N, 19.82

Example 17

5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-3-nitro-1H-pyrrole-2- carbonitrile

10 To 4,4-Dimethyl-6-(5-cyano-1H-pyrrol-2-yl)-1,4-dihydrobenzo [d][1,3]oxazin-
2-one (0.3 g, 1.2 mmol, 1 eq) in acetic anhydride (7.3 mL) was added Cu(NO₃)₂•2.5
H₂O (0.15 g, 0.65 mmol, 0.55 eq). After the reaction mixture stirred at room
temperature for 2h, it was poured into saturated aqueous sodium bicarbonate solution
(50 mL) and extracted with ethyl acetate (2 x 50 mL). The organic layers were
15 combined, washed with water (50 mL) and brine (50 mL), dried over magnesium
sulfate, filtered and concentrated *in vacuo*. The residue crystallized from
dichloromethane/acetone to give the product as a yellow solid (48 mg, 13%). The
filtrate (0.3 g) was placed aside. ¹H NMR (300 MHz, *d*₆-DMSO) δ 1.65 (s, 6 H), 6.94
(d, 1 H, *J* = 8.3 Hz), 7.51 (s, 1 H), 7.73(d, 1 H, *J* = 8.3 Hz), 7.78 (s, 1 H), 10.46 (s, 1
20 H), 13.84 (s, 1 H). MS (ESI (-)) [M-H]⁺ *m/z* 311. Anal. calcd. for C₁₅H₁₂N₄O₄: C,
57.69; H, 3.87; N, 17.94. Found: C, 57.91; H, 3.96, N, 17.41.

Example 18

3-amino-5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrole-2- carbonitrile

25 To 5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-3-nitro-1H-
pyrrole-2-carbonitrile (0.14 g, 0.45 mmol) in EtOH/H₂O (5:1, 20 mL:4 mL) was added
Zn powder (0.35 g, 5.3 mmol) and NH₄Cl (0.70 g, 13 mmol) and the mixture was
heated to 60 °C for 25 min. After cooling to room temperature and stirring 24 h, the
30 reaction mixture was diluted with ethyl acetate (100 mL) and filtered through a pad of

celite. The filtrate was washed with water (50 mL) and brine (50 mL), dried over magnesium sulfate, filtered and concentrated *in vacuo*. Purification by flash column chromatography (60% ethyl acetate/hexane) on silica gel gave the product as an orange foam (30 mg, 24 %). ¹H NMR (500 MHz, *d*₆-DMSO) δ 1.63 (s, 6 H), 5.01 (s, 2 H), 5.95 (d, 1 H, *J* = 2.9 Hz), 6.87 (d, 1 H, *J* = 8.3 Hz), 7.48 (dd, 1 H, *J* = 2.0, 8.3 Hz), 7.54 (d, 1 H, *J* = 2.0 Hz), 10.30 (s, 1 H), 11.17 (d, 1 H, *J* = 2.5 Hz). MS (ESI) [M-H]⁺ *m/z* 281.

Example 19

10 5-(4,4-Dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1,3,4-trimethyl-1H-pyrrole-2-carbonitrile

To a solution of 5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1,4-dimethyl-1H-pyrrole-2-carbonitrile (1 eq, 0.15 g, 0.51 mmol) in THF (5 mL) at -78 °C was added N-bromosuccinimide (1.1 eq, 0.1 g, 0.56 mmol). The solution was allowed to warm and stir for 16 hours. Pyridine (1 mL) was added and the mixture was poured into water (15 mL), the layers were separated, the aqueous layer was extracted with ethyl acetate (3 x 10 mL) and the combined organic layer was washed with brine, dried over MgSO₄ and concentrated *in vacuo*. The product, 5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-3-bromo-1,4-dimethyl-1H-pyrrole-2-carbonitrile was obtained by crystallization from 20% ethyl acetate/hexane as a white crystalline solid. ¹H NMR (300 MHz, *d*₆-DMSO) δ 1.64 (s, 6H), 1.93 (s, 3H), 3.57 (s, 3H), 7.01 (d, 1H, *J*=8Hz), 7.31 (dd, 1H, *J*=1.95, 8Hz), 7.35 (s, 1H), 10.43 (s, 1H). MS *m/z* (ESI (-)) 372/374 (M-H)⁺. Anal. calcd for C₁₇H₁₆N₃O₂, C, 54.6, H, 4.31, N, 11.2. Found, C, 54.8, H, 4.42, N, 11.1.

25 A solution of 5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-3-bromo-1,4-dimethyl-1H-pyrrole-2-carbonitrile (0.11 g, 0.29 mmol), PhCNPdCl(PPh₃)₂ (cat., 11 mg) and tetramethyltin (10 eq, 0.53 g, 2.9 mmol) in HMPA (3 mL) was heated to 110 °C for 5d. The solution was allowed to cool, poured into water (20 mL) and extracted with ethyl acetate (3 x 15 mL). The combined organic layer was washed with brine, dried over MgSO₄ and purified by flash column chromatography on silica

30

gel eluting with 30% ethyl acetate/hexane to give 5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1,3,4-trimethyl-1H-pyrrole-2-carbonitrile (77 mg, 85%) as a white solid. ¹H NMR (300 MHz, *d*₆-DMSO) δ 1.63 (s, 6H), 1.87 (s, 3H), 2.49 (s, 3H), 3.50 (s, 3H), 6.99 (d, 1H, *J*=8.2Hz), 7.25 (dd, 1H, *J*=8.2, 1.4Hz), 7.29 (s, 1H), 10.39 (s, 1H). MS (ESI (-)) 308 (M-H)⁺. Anal. calcd for C₁₈H₁₉N₃O₄, C, 69.9, H, 6.19, N, 13.6. Found, C, 68.8, H, 6.22, N, 12.9.

Example 20

4-bromo-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrole-2-carbonitrile


10

To 4,4-Dimethyl-6-(5-cyano-1H-pyrrol-2-yl)-1,4-dihydrobenzo [d][1,3]oxazin-2-one (0.625 g, 2.3 mmol, 1 eq) in THF (anhydrous, 60 mL) was added NBS (0.46 g, 2.5 mmol, 1.1 eq) at -78 °C. After 1 h, the reaction was warmed to room temperature, poured into water (100 mL) and extracted with ethyl acetate (2 x 100 mL). The organic layers were combined, washed with aqueous 10 % sodium bisulfite solution (50 mL), water (50 mL) and brine (50 mL), dried over magnesium sulfate, filtered and concentrated *in vacuo*. Crystallization from 20% ethyl acetate/hexane gave the product (40 mg, 5%) as a white solid. The filtrate (0.5 g) was placed aside. ¹H NMR (300 MHz, *d*₆-DMSO) δ 1.64 (s, 6 H), 6.98 (d, 1 H, *J* = 8.2 Hz), 7.19 (d, 1 H, *J* = 1.4 Hz), 7.57 (s, 1 H), 7.62 (dd, 1 H, *J* = 1.4, 8.3 Hz), 10.43 (s, 1 H), 12.91 (s, 1 H). MS (ESI) [M-H]⁺ *m/z* 344/346. Anal. calcd. for C₁₅H₁₂BrN₃O₂: C, 52.04; H, 3.49; N, 12.14. Found: C, 51.4; H, 3.57, N, 11.59.

All publications cited in this specification are incorporated herein by reference herein. While the invention has been described with reference to a particularly preferred embodiment, it will be appreciated that modifications can be made without departing from the spirit of the invention. Such modifications are intended to fall within the scope of the appended claims.

WHAT IS CLAIMED IS:

1. A compound formula 1 having the structure



1

wherein

T is O, S, or absent;

- 10 R₁, and R₂ are each, independently, hydrogen, alkyl, substituted alkyl; or

R₁ and R₂ are taken together form a ring and together contain -CH₂(CH₂)_nCH₂-,
-CH₂CH₂CMe₂CH₂CH₂-, -O(CH₂)_pCH₂-, -O(CH₂)_qO-, -CH₂CH₂OCH₂CH₂-,
or -CH₂CH₂N R₇CH₂CH₂-;

n = 1-5;

- 15 p = 1-4;

q = 1-4

R₃ is hydrogen, OH, NH₂, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl,
substituted alkynyl, or COR^A;

R^A is hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or
20 substituted aminoalkyl;

R₄ is hydrogen, halogen, CN, NH₂, alkyl, substituted alkyl, alkoxy, substituted alkoxy,
aminoalkyl, or substituted aminoalkyl;

R₅ is hydrogen, alkyl, or substituted alkyl;

R₆ is hydrogen, alkyl, substituted alkyl, or COR^B;

- 25 R^B is hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or
substituted aminoalkyl;

R₇ is hydrogen or alkyl;

or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1, wherein
wherein

5 T is O, or absent;

R₁, and R₂ are each, independently, hydrogen, alkyl, substituted alkyl; or

R₁ and R₂ are taken together form a ring and together contain -CH₂(CH₂)_nCH₂- ;

n = 1-5;

R₃ is hydrogen;

10 R₄ is hydrogen or halogen;

R₅ is hydrogen or alkyl;

R₆ is hydrogen or alkyl;

or a pharmaceutically acceptable salt thereof.


15 3. The compound according to claim 1, which is 5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-benzo [d] [1,3] oxazin-6-yl)-1H-pyrrole-2-carbonitrile or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1, which is 5-(2'-Oxo-2',3'-dihydrospiro[cyclohexane-
20 1,3'-[3H]indol]-5'-yl)-2-cyanopyrrole or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1, which is 2-(3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-2-cyanopyrrole or a pharmaceutically acceptable salt thereof.

25 6. The compound of claim 1, which is 5-(2'-Oxo-2',3'-dihydrospiro[cyclopentane-1,3'-[3H]indol]-5'-yl)-2-cyanopyrrole or a pharmaceutically acceptable salt thereof.

6. A method of providing progestational therapy to a mammal in need thereof which comprises administering a progestationally effective amount of compound formula 1 having the structure



1

wherein

T is O, S, or absent;

10 R₁, and R₂ are each, independently, hydrogen, alkyl, substituted alkyl; or

R₁ and R₂ are taken together form a ring and together contain -CH₂(CH₂)_nCH₂- ,
-CH₂CH₂CMe₂CH₂CH₂- , -O(CH₂)_pCH₂- , -O(CH₂)_qO- , -CH₂CH₂OCH₂CH₂- ,
or -CH₂CH₂NR₇CH₂CH₂-;

n = 1-5;

15 p = 1-4;

q = 1-4

R₃ is hydrogen, OH, NH₂, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl,
substituted alkynyl, or COR^A;

20 R^A is hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or
substituted aminoalkyl;

R₄ is hydrogen, halogen, CN, NH₂, alkyl, substituted alkyl, alkoxy, substituted alkoxy,
aminoalkyl, or substituted aminoalkyl;

R₅ is hydrogen, alkyl, or substituted alkyl;


R₆ is hydrogen, alkyl, substituted alkyl, or COR^B;

25 R^B is hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or
substituted aminoalkyl;

R₇ is hydrogen or alkyl;

or a pharmaceutically acceptable salt thereof, to said mammal.

7. A method of treating or inhibiting breast, uterine, ovarian, endometrial, or prostate cancer which comprises administering a compound formula 1 having the structure



1

10 wherein

T is O, S, or absent;

R₁, and R₂ are each, independently, hydrogen, alkyl, substituted alkyl; or

R₁ and R₂ are taken together form a ring and together contain -CH₂(CH₂)_nCH₂-,
-CH₂CH₂CMe₂CH₂CH₂-, -O(CH₂)_pCH₂-, -O(CH₂)_qO-, -CH₂CH₂OCH₂CH₂-,

15 or -CH₂CH₂NR₇CH₂CH₂-;

n = 1-5;

p = 1-4;

q = 1-4

R₃ is hydrogen, OH, NH₂, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl,

20 substituted alkynyl, or COR^A;

R^A is hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl;

R₄ is hydrogen, halogen, CN, NH₂, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl;

25 R₅ is hydrogen, alkyl, or substituted alkyl;


R₆ is hydrogen, alkyl, substituted alkyl, or COR^B;

R^B is hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl;

R₇ is hydrogen or alkyl;

or a pharmaceutically acceptable salt thereof, to said mammal.

8. A method of providing contraception in a mammal in need thereof, which
5 comprises administering an effective amount compound formula 1 having the structure



1

10 wherein

T is O, S, or absent;

R₁, and R₂ are each, independently, hydrogen, alkyl, substituted alkyl; or

R₁ and R₂ are taken together form a ring and together contain -CH₂(CH₂)_nCH₂- ,
-CH₂CH₂CMe₂CH₂CH₂- , -O(CH₂)_pCH₂- , -O(CH₂)_qO- , -CH₂CH₂OCH₂CH₂- ,

15 or -CH₂CH₂NR₇CH₂CH₂-;

n = 1-5;

p = 1-4;

q = 1-4

20 R₃ is hydrogen, OH, NH₂, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl,
substituted alkynyl, or COR^A;

R^A is hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or
substituted aminoalkyl;

R₄ is hydrogen, halogen, CN, NH₂, alkyl, substituted alkyl, alkoxy, substituted alkoxy,
aminoalkyl, or substituted aminoalkyl;

25 R₅ is hydrogen, alkyl, or substituted alkyl;

R₆ is hydrogen, alkyl, substituted alkyl, or COR^B;


R^B is hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl;

R_7 is hydrogen or alkyl;

or a pharmaceutically acceptable salt thereof, to said mammal.

5

9. A pharmaceutical composition, which comprises a compound formula 1 having the structure



1

10

wherein

T is O, S, or absent;

R_1 , and R_2 are each, independently, hydrogen, alkyl, substituted alkyl; or

15 R_1 and R_2 are taken together form a ring and together contain $-\text{CH}_2(\text{CH}_2)_n\text{CH}_2-$, $-\text{CH}_2\text{CH}_2\text{CMe}_2\text{CH}_2\text{CH}_2-$, $-\text{O}(\text{CH}_2)_p\text{CH}_2-$, $-\text{O}(\text{CH}_2)_q\text{O}-$, $-\text{CH}_2\text{CH}_2\text{OCH}_2\text{CH}_2-$, or $-\text{CH}_2\text{CH}_2\text{NR}_7\text{CH}_2\text{CH}_2-$;

$n = 1-5$;

$p = 1-4$;

20 $q = 1-4$

R_3 is hydrogen, OH, NH_2 , alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, or COR^A ;

R^A is hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl;

25 R_4 is hydrogen, halogen, CN, NH_2 , alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl;

R_5 is hydrogen, alkyl, or substituted alkyl;

R_6 is hydrogen, alkyl, substituted alkyl, or COR^B ;

R^B is hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl;

R_7 is hydrogen or alkyl;

- 5 or a pharmaceutically acceptable salt thereof and a pharmaceutical carrier.

INTERNATIONAL SEARCH REPORT

Int'l Application No

PCT/US 00/11844

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D413/04 C07D403/04 A61K31/40 A61P15/16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 13767 A (CHEMISCH PHARMAZEUTISCHE FORSCHUNGSGESELLSCHAFT MBH) 17 April 1997 (1997-04-17) claims 1-10	1-9
A	US 5 808 139 A (I. CHARLES PATHIRANA ET AL.) 15 September 1998 (1998-09-15) claims 1-27	1-9

☐ Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

18 August 2000

Date of mailing of the international search report

29/08/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Herz, C

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US 00/11844

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9713767 A	17-04-1997	AU 7284096 A	30-04-1997
US 5808139 A	15-09-1998	AU 4117093 A	18-11-1993
		AU 5664194 A	08-11-1994
		CA 2133325 A	28-10-1993
		EP 0637296 A	08-02-1995
		MX 9302312 A	30-06-1994
		WO 9321145 A	28-10-1993
		WO 9424080 A	27-10-1994